← Back to Search

recombinant human annexin A5 for Coronavirus (AX-COVID Trial)

Phase 2
Waitlist Available
Led By Claudio Martin, MD, MSc
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Admitted to intensive care for organ failure support (at least one of vasopressor, non-invasive or invasive ventilation)
Age ≥ 19 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

AX-COVID Trial Summary

This trial is testing a potential new treatment for severe coronavirus disease. It is comparing SY-005 (a recombinant human Annexin A5) to a placebo to see if it is effective. The trial is double-blind, meaning that neither the patients nor the doctors know who is receiving the SY-005 or the placebo.

Eligible Conditions
  • Coronavirus
  • Sepsis

AX-COVID Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

AX-COVID Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Data completeness
Enrollment
Protocol adherence
Secondary outcome measures
Elimination half-life of annexin A5 (SY-005)
Hospital mortality
ICU-free days
+14 more

AX-COVID Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low doseExperimental Treatment1 Intervention
50 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
Group II: High doseExperimental Treatment1 Intervention
100 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
Group III: PlaceboPlacebo Group1 Intervention
Normal saline, 50 ml infusion over 30 minutes every 12 hours for 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
recombinant human annexin A5
2021
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
654 Previous Clinical Trials
413,167 Total Patients Enrolled
London Health Sciences FoundationUNKNOWN
2 Previous Clinical Trials
42 Total Patients Enrolled
Ontario Ministry of Colleges and UniversitiesUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has recombinant human annexin A5 received FDA approval yet?

"While there is limited data on recombinant human annexin A5's efficacy, what evidence exists suggest it is safe."

Answered by AI

To date, how many individuals have opted into this clinical trial?

"That is correct, the clinical trial is still actively recruiting patients. The first posting was on April 20th 2021 with the most recent update occurring on April 23rd of this year. They are looking for a total of 60 individuals across a single site."

Answered by AI

What are the goals of this experiment?

"The 12-month study will focus on Protocol adherence, with secondary objectives being to track the number of patients with organ dysfunction and ventilator usage."

Answered by AI

Are there any current vacancies for patients in this clinical trial?

"The clinicaltrials.gov website shows that this study is still recruiting patients. It was originally posted on 4/20/2021, with the most recent update being from 4/23/2021."

Answered by AI
~5 spots leftby Mar 2025